# The Effect Of Tafamidis Meglumine In Transthyretin Amyloid Polyneuropathy Patients

> **NCT04828993** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 15 (actual)

## Conditions studied

- Transthyretin Amyloid Polyneuropathy (ATTR-PN)

## Interventions

- **DRUG:** tafamidis meglumine

## Key facts

- **NCT ID:** NCT04828993
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-28
- **Primary completion:** 2023-02-12
- **Final completion:** 2023-02-12
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04828993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04828993, "The Effect Of Tafamidis Meglumine In Transthyretin Amyloid Polyneuropathy Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04828993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*